Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight(GlaxoSmithKline (United States)), Dashyant Dhanak(Wilmington University), Richard R. Gontarek(South College), David Sutton(South College), Martha A. Sarpong(South College), Juan I. Luengo(South College), Christine Gardiner(South College), P.A. Elkins(South College), S. Gilbert, Carla A. Donatelli(South College), Michael G. Darcy(South College), Eric Garver(South College), Amita M. Chaudhari(South College), Peter J. Tummino(Intarcia Therapeutics (United States)), Christian Sherk(GlaxoSmithKline (United States)), Ronald Wegrzyn(South College), Stanley J. Schmidt(South College), Glenn S. Van Aller(GlaxoSmithKline (United Kingdom)), Kevin L. Kershner(South College), Joelle L. Burgess(GlaxoSmithKline (United States)), Kaushik Raha(RELX Group (Netherlands)), Lusong Luo(Beijing Biocytogen (China)), Jeffrey R. Jackson(New Frontier), K. A. NEWLANDER(South College), Chiu-Mei Sung(South College), Kurt R. Auger(Research Triangle Park Foundation), Melody Diamond(South College), Cynthia A. Parrish(South College), Lance H. Ridgers(South College), Nicholas D. Adams(South College), Jeffrey D. Carson(GlaxoSmithKline (United States))
ACS Medicinal Chemistry Letters
January 19, 2010
Cited by 374


Related Papers